glp-1 receptor agonist agonists and next-generation metabolic hormone therapies in chronic kidney disease Targeting GLP-1, GIP & GCG

Both membrane-associated and soluble DPP-4 exert catalytic activity, cleaving proteins containing a position 2 alanine or proline

Abstract Medications like liraglutide 3.0 mg daily (Saxenda

The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD) Metabolism

Rising disposable incomes, growing recognition of diabetes-related risks, and government efforts to enhance chronic disease management are expected to support substantial market growth for GLP-1 receptor agonists across Asia Pacific

Among patients who previously used a GLP-1-based medication, most switched from injectable anti-obesity medications (AOM), including injectable AOM semaglutide (sold as Wegovy) and AOM tirzepatide (sold as Zepbound)

Table 11 Clinical and research-stage translational status of diagnostic tools